TRAXENS
28.5.2019 09:02:10 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, announces today that its patented cargo tracking IoT system will be used on CFL multimodal’s connected freight wagons throughout the European corridor and the New Silk Road to China.
Traxens and CFL multimodal (CFL) started their co-operation with a pilot project at the end of 2018, when CFL fitted Traxens Box devices on flat wagons travelling between European destinations. As this initial trial was successful, it was extended earlier this year to over 20 wagons delivering cargo to more distant European destinations. In April 2019 Traxens’ rail freight telematics technology was then tested on wagons travelling to China.
As part of it digitalization strategy, CFL aims to streamline train preparation operations through automation, including digital brake testing. Traxens’ Digital Freight Train® solutions can consolidate, secure and accelerate brake safety testing. This testing system can bring a number of benefits:
- Thirty minutes saved on standard reallocation processes to improve robustness or optimize loading
- Continuous monitoring of the brake system after departure, with real-time alerts for the train driver to prevent a flat wheel
- Improved safety and working conditions for shunting and ground operators who perform brake tests
- Can be used solely by the train driver instead of two agents — reducing operating costs and improving agility and quality of the whole system
- In the longer term, it will allow the interconnection of operators systems to improve interoperability and international trade, leading to better global efficiency of rail freight
Traxens’ solution provides comprehensive, precise and timely data about cargo by tracking wagons in transit anywhere in the world. Traxens’ technology brings improved efficiency and security, greater transparency and enhanced asset utilization thanks to improved wagons and goods tracking, geolocalisation and mileage monitoring.
The Traxens Box is straightforward to install within a few minutes whether on the customers’ sites, at railway terminals or workshops; it can be adapted to any type of wagon.
“As an outcome of our joint pilot project, we are delighted that CFL multimodal decided to extend its use of our bespoke IoT technology in its rail freight operations to China,” said Florence Delalande, rail business unit director at Traxens. “This shows the potential of our technology for all rail and intermodal freight businesses, as the shipping industry shifts towards a digital future.”
“Traxens’ rail freight solution helps our operations by enabling the monitoring of assets and their surroundings, which significantly improves operational efficiency,” said Marc Valette, innovation director at CFL multimodal. “The technology used by Traxens, enabling the local interconnection of different devices without wiring, opens up new opportunities in train condition and composition monitoring. This is a huge opportunity to improve operations and service effectiveness in rail. It will allow the connection of different elements of the train ecosystem in the future, providing transparent and accurate information, improving the quality of service and information delivered to clients.”
This agreement with CFL Multimodal is the latest development for Traxens in the rail sector. Traxens has already started cooperations with other key players in the industry, such as SNCF (the French national railway company). In cooperation with SNCF Logistics, Traxens developed the Digital Freight Train and its high value-added services for the benefit of the entire railway system, by turning conventional wagons into intelligent wagons in record time. It features geolocation, arrival notifications, consignment transport conditions and status monitoring, digital assistance for wagon management, predictive maintenance and more. Traxens offers a whole range of services for a safer, more modern, eco-friendly and more efficient freight railway system.
This year Traxens has already won several innovation awards for its Digital Freight Train project.
About CFL Multimodal
CFL multimodal is a logistics service
provider, covering the entire logistics chain. With 12 companies in six
European countries, CFL multimodal and its sister company CFL cargo
offer a broad and customised service portfolio: combined and
conventional rail freight, wagon maintenance and repairs, customs
clearance, as well as forwarding and logistics services. In Luxembourg,
the activities of CFL multimodal are organised around the intermodal
terminal of Bettembourg-Dudelange on the Eurohub South Logistics Park.
Located on the Rail Freight Corridor 2 (North Sea-Mediterranean) and at
the crossroads of major transport routes, the terminal is ideally
positioned as an international hub for the consolidation of multimodal
transport flows across Europe and beyond. With a total yearly capacity
of 600,000 units and equipped with the latest technology in terms of
security and surveillance, the intermodal terminal is connected by
combined train shuttles to the main ports and industrial regions.
www.cfl-mm.lu
ABOUT TRAXENS
Traxens generates, collects, consolidates,
enriches and transforms logistics asset data into actionable insight for
its clients in the maritime, rail and supply chain industries.
The
company’s breakthrough Internet-of-Big-Things technology provides
comprehensive, real-time information for managing logistics assets
anywhere in the world. Traxens’ solutions digitally transform
multi-modal supply chains, enabling customers to reduce costs, optimize
investments, comply with environmental regulations and deliver premium
services to their customers. Traxens’ IoT solution received the Frost &
Sullivan’s Technology Leadership Award in 2019.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005138/en/
Contact:
PRESS: Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
